scispace - formally typeset
M

Mehrdad Nadji

Researcher at University of Miami

Publications -  153
Citations -  5793

Mehrdad Nadji is an academic researcher from University of Miami. The author has contributed to research in topics: Carcinoma & Cancer. The author has an hindex of 43, co-authored 150 publications receiving 5588 citations. Previous affiliations of Mehrdad Nadji include Roswell Park Cancer Institute & University of Oviedo.

Papers
More filters
Journal ArticleDOI

Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms

TL;DR: This is the first immununohistochemical marker for prostate gland epithelium which does not represent prostatic acid phosphatase and is likely to be a diagnostic histologic marker for tumors of prostatic origin.
Journal ArticleDOI

Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer

TL;DR: Increased HA levels are found in prostate cancer (CaP) tissues when compared with normal (NAP) and benign (BPH) tissues and stromal-epithelial HA and HYAL1 expression may promote angiogenesis in CaP and may serve as prognostic markers for CaP.
Book ChapterDOI

Receptors reconsidered: a 20-year perspective.

TL;DR: The biochemical mechanism by which the reaction of estradiol and other estrogenic hormones with receptor substances elicits hormonal response has been the subject of extensive investigation and appears to be characteristically restricted in hormone-dependent tissues.
Journal ArticleDOI

A Tissue Fixative that Protects Macromolecules (DNA, RNA, and Protein) and Histomorphology in Clinical Samples

TL;DR: It is concluded that it is now possible to preserve histomorphology and intact macromolecules in the same archival paraffin-embedded tissue through the use of a novel fixative and a rapid processing system.
Journal ArticleDOI

Surgically defined prognostic parameters in patients with early cervical carcinoma: A multivariate survival tree analysis

TL;DR: The main goal of the study was to identify subsets of patients based on risk factors with maximal differences in DFS that best predict 5‐year disease free survival in patients with early stage cervical carcinoma treated by radical hysterectomy.